EP Patent

EP4285894A1 — A formulation of empagliflozin and metformin hydrochloride

Assigned to Sanovel Ilac Sanayi ve Ticaret AS · Expires 2023-12-06 · 2y expired

What this patent protects

The present invention relates to a film coated tablet comprising an intragranular composition comprising empagliflozin and metformin hydrochloride and at least one binder, wherein the intragranular composition is obtained by wet-granulation using a solvent comprising alcohol. The…

USPTO Abstract

The present invention relates to a film coated tablet comprising an intragranular composition comprising empagliflozin and metformin hydrochloride and at least one binder, wherein the intragranular composition is obtained by wet-granulation using a solvent comprising alcohol. The process is simple, rapid, cost effective, time-saving and industrially convenient process.

Drugs covered by this patent

Patent Metadata

Patent number
EP4285894A1
Jurisdiction
EP
Classification
—
Expires
2023-12-06
Drug substance claim
No
Drug product claim
No
Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.